Key Words:
cancer, antibody drug conjugates, gold, Trastuzumab, phosphane,
N-heterocyclic carbenes
This invention’s purpose is the development of novel targeted chemotherapeutics for the treatment of cancer based on gold compounds. This invention improves the delivery of these drugs so that they can be efficiently released at the specific tumor site without affecting healthy
tissues. More specifically, the invention describes synthetic procedures to prepare antibody drug conjugates containing gold compounds. While these strategies can be applied to different antibodies, the preliminary data we have is for Trastuzumab (HerceptinTM, Genentech) a humanised IgG1 mAb which has been exploited successfully as both a therapeutic agent and radiotracer. Its main use in cancer therapy has been for breast cancer. Our in vitro preliminary
data is for breast cancer cell lines.
For more information or to license this innovation:
- Log In
to view the innovation's details
- Sign Up
with discount code "ECOS"